PHBBF Quote, Financials, Valuation and Earnings

Prenetics Global has a net margin of -- compared to Pharmaron Beijing's net margin of -137.21%. Pharmaron Beijing's return on equity of -- beat Prenetics Global's return on equity of -23.16%.

Pharmaron Beijing has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global has an analysts' consensus of $9.00 which suggests that it could grow by 55.44%. Given that Prenetics Global has higher upside potential than Pharmaron Beijing, analysts believe Prenetics Global is more attractive than Pharmaron Beijing.

Pharmaron Beijing has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prenetics Global has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pharmaron Beijing has a quarterly dividend of $0.03 per share corresponding to a yield of 3.64%. Prenetics Global offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmaron Beijing pays -- of its earnings as a dividend. Prenetics Global pays out -- of its earnings as a dividend.

Pharmaron Beijing quarterly revenues are --, which are smaller than Prenetics Global quarterly revenues of $7.8M. Pharmaron Beijing's net income of -- is lower than Prenetics Global's net income of -$10.7M. Notably, Pharmaron Beijing's price-to-earnings ratio is -- while Prenetics Global's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing is 1.44x versus 2.79x for Prenetics Global. Usually stocks with elevated PS ratios are considered overvalued.

Regencell Bioscience Holdings has a net margin of -- compared to Pharmaron Beijing's net margin of --. Pharmaron Beijing's return on equity of -- beat Regencell Bioscience Holdings's return on equity of --.

Pharmaron Beijing has a consensus price target of --, signalling downside risk potential of --. On the other hand Regencell Bioscience Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Pharmaron Beijing has higher upside potential than Regencell Bioscience Holdings, analysts believe Pharmaron Beijing is more attractive than Regencell Bioscience Holdings.

Pharmaron Beijing has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regencell Bioscience Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pharmaron Beijing has a quarterly dividend of $0.03 per share corresponding to a yield of 3.64%. Regencell Bioscience Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmaron Beijing pays -- of its earnings as a dividend. Regencell Bioscience Holdings pays out -- of its earnings as a dividend.

Pharmaron Beijing quarterly revenues are --, which are smaller than Regencell Bioscience Holdings quarterly revenues of --. Pharmaron Beijing's net income of -- is lower than Regencell Bioscience Holdings's net income of --. Notably, Pharmaron Beijing's price-to-earnings ratio is -- while Regencell Bioscience Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing is 1.44x versus -- for Regencell Bioscience Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Sino Biopharmaceutical has a net margin of -- compared to Pharmaron Beijing's net margin of --. Pharmaron Beijing's return on equity of -- beat Sino Biopharmaceutical's return on equity of 10.53%.

Pharmaron Beijing has a consensus price target of --, signalling downside risk potential of --. On the other hand Sino Biopharmaceutical has an analysts' consensus of -- which suggests that it could fall by --. Given that Pharmaron Beijing has higher upside potential than Sino Biopharmaceutical, analysts believe Pharmaron Beijing is more attractive than Sino Biopharmaceutical.

Pharmaron Beijing has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sino Biopharmaceutical has a beta of 0.538, suggesting its less volatile than the S&P 500 by 46.165%.

Pharmaron Beijing has a quarterly dividend of $0.03 per share corresponding to a yield of 3.64%. Sino Biopharmaceutical offers a yield of 2.49% to investors and pays a quarterly dividend of $0.00 per share. Pharmaron Beijing pays -- of its earnings as a dividend. Sino Biopharmaceutical pays out 27.13% of its earnings as a dividend. Sino Biopharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pharmaron Beijing quarterly revenues are --, which are smaller than Sino Biopharmaceutical quarterly revenues of --. Pharmaron Beijing's net income of -- is lower than Sino Biopharmaceutical's net income of --. Notably, Pharmaron Beijing's price-to-earnings ratio is -- while Sino Biopharmaceutical's PE ratio is 24.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing is 1.44x versus 1.97x for Sino Biopharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Uni-Bio Science Group has a net margin of -- compared to Pharmaron Beijing's net margin of --. Pharmaron Beijing's return on equity of -- beat Uni-Bio Science Group's return on equity of --.

Pharmaron Beijing has a consensus price target of --, signalling downside risk potential of --. On the other hand Uni-Bio Science Group has an analysts' consensus of -- which suggests that it could fall by --. Given that Pharmaron Beijing has higher upside potential than Uni-Bio Science Group, analysts believe Pharmaron Beijing is more attractive than Uni-Bio Science Group.

Pharmaron Beijing has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Uni-Bio Science Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pharmaron Beijing has a quarterly dividend of $0.03 per share corresponding to a yield of 3.64%. Uni-Bio Science Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmaron Beijing pays -- of its earnings as a dividend. Uni-Bio Science Group pays out -- of its earnings as a dividend.

Pharmaron Beijing quarterly revenues are --, which are smaller than Uni-Bio Science Group quarterly revenues of --. Pharmaron Beijing's net income of -- is lower than Uni-Bio Science Group's net income of --. Notably, Pharmaron Beijing's price-to-earnings ratio is -- while Uni-Bio Science Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing is 1.44x versus -- for Uni-Bio Science Group. Usually stocks with elevated PS ratios are considered overvalued.